Skip to main navigation
  • Follow Us:
  • Grant Portal
Catalystpharma.com

Corporate Menu

  • About Catalyst
    • History
    • Management
    • Board Of Directors
    • News & Events
    • Careers
    • Contact Us
  • Patient Focus
    • Patient Stories
      • LEMS Stories
    • Disease Information
      • LEMS
      • MuSK-MG
      • SMA
    • Patient Resources
      • Organizations
      • Event Calendar
      • Patient Engagement
  • Research & Pipeline
    • Roadmap To Success (Strategy)
    • Pipeline (clinical)
      • LEMS Clinical
      • MuSK-MG Clinical
      • SMA Clinical
    • Product
    • Business Development
    • Healthcare Professional Outreach
  • Clinical Trials
  • Responsibility
    • Corporate Giving
    • Investigator Sponsored Research
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Board of Directors
      • Management
      • Committee Composition
      • Contact the Board
    • Stockholder Rights Plan
    • Financials
      • SEC Filings
      • Annual Report and Proxy
      • Key Ratios
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Contact Us
Select Page
Investors

Volume
52 Week High
52 Week Low
Feb 12, 2021 10:09 PM EST
Copyright Nasdaq. Minimum 15 minutes delayed.

Mobile Menu

  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Board of Directors
    • Management
    • Committee Composition
    • Contact the Board
  • Stockholder Rights Plan
  • Financials
    • SEC Filings
    • Annual Report and Proxy
    • Key Ratios
  • Stock Information
    • Historic Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Contact Us

Investors

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), MuSK antibody positive myasthenia gravis (MuSK-MG), and spinal muscular atrophy (SMA) Type 3. 

The US FDA approved FIRDAPSE® (amifampridine) tablets for use in adults with LEMS on November 28, 2018, and FIRDAPSE was commercially available in January 2019

Catalyst is in the early stages of developing a long acting formulation of FIRDAPSE


 

Events & Presentations

Feb 21, 2019
Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders
More

Latest Press Releases

Feb 22, 2021
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
Jan 06, 2021
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update
More

Annual Reports and Proxy Statement

2019 Annual Report
2020 Proxy Statement
2018 Annual Report
More

Toolkit

  • Email Alerts

  • RSS

  • Print page

  • Search

Footer Menu

  • ABOUT CATALYST
  • PATIENT FOCUS
  • RESPONSIBILITY
  • RESEARCH & PIPELINE
  • NEWS & EVENTS
  • CAREERS
  • CONTACT US
  • CLINICAL TRIALS
CONTACT
(305) 420-3200
Email Us


FOLLOW US:
facebook twitter linkedin
© 2020 Catalyst Pharmaceuticals, Inc. All Rights Reserved. 19CRP0211(3) November 2019 | Privacy Policy